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In the aluminum age, it is clearly unpalatable for aluminum, the globe’s most success-
ful metal, to be implicated in human disease. It is unpalatable because for approximately
100 years human beings have reaped the rewards of the most abundant metal of the Earth’s
crust without seriously considering the potential consequences for human health.The alu-
minum industry is a pillar of the developed and developing world and irrespective of the
tyranny of human exposure to aluminum it cannot be challenged without significant con-
sequences for businesses, economies, and governments. However, no matter how deep
the dependency or unthinkable the withdrawal, science continues to document, if not too
slowly, a burgeoning body burden of aluminum in human beings. Herein, I will make the
case that it is inevitable both today and in the future that an individual’s exposure to alu-
minum is impacting upon their health and is already contributing to, if not causing, chronic
diseases such as Alzheimer’s disease. This is the logical, if uncomfortable, consequence
of living in the aluminum age.
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INTRODUCTION
In 1970, it was believed that the phosphorylation of glucose by hex-
okinase in the presence of ATP required certain“activators,”such as
citrate, and especially so at circumneutral pH (1). In 1979, the so-
called allosteric activity of citrate (and other activators) was found
to be the consequence of the contamination of laboratory supplies
of ATP by aluminum (2). The same problems of contamination
are an issue today (3, 4) and though the level of contamination is
usually no higher than 0.1% (1 Al for every 1000 ATP) the avidity
with which ATP binds Al(III) relative to its usual co-factor Mg(II)
(ca 103 times higher) means that when Al-ATP replaces Mg-ATP
as a source of phosphate the subsequent activity of hexokinase
will be significantly diminished. Under the same conditions but
additionally in the presence of citrate (a significant competitor for
Al(III) binding at pH≥ 7) Al-ATP dissociates and the formation of
Al-citrate complexes protects the enzyme–substrate complex from
the inhibitory actions of Al-ATP. This account of the consequence
of the contamination of commercial supplies of ATP by Al(III) is in
itself an important lesson but it also has wider implications for the
arrival of Al(III) in biota and specifically human beings. There are
few more fundamental reactions in human biochemistry than the
phosphorylation of glucose using ATP and it should be clear to all
that such a reaction would not have been selected for in human bio-
chemistry in the presence of biologically available Al(III) (5). The
insidious advent of the aluminum age has been and will continue
to be heralded by burgeoning examples of the biological availabil-
ity of Al(III) and it is of critical importance that we both recognize
this fact and, concomitantly, prepare ourselves to counter any role
that Al(III) might be playing in human disease. Currently, political
aspects of the use of aluminum are preventing a common sense
approach to living in the aluminum age and complacency is ensur-
ing an accelerated exposure to aluminum in our everyday lives and
a burgeoning body burden of aluminum for each and every one
of us. In extending the paradigm of ATP’s contamination by alu-
minum, one could say that laboratory Earth’s supplies of human
beings are already significantly contaminated with aluminum and
it is now an active participant in human evolution.
COMPLACENCY AND ALUMINUM
The most significant factor driving complacency about the poten-
tial dangers of aluminum is its omnipresence in modern life. Many
will have attended scientific meetings where one of the “aluminum
ambassadors” for the industry would give a presentation on how
aluminum’s omnipresence was a sure sign of its essentiality. The
logic goes that since it is present in every cell then it must be bene-
ficial, we just do not know how it is beneficial. Today, we all have a
body burden of aluminum and it is likely that it is present in every
physical and chemical compartment in the human body. It is also
true to say that it is burgeoning and tomorrow’s generation will
have a higher body burden of aluminum (6). However, we have
yet to identify a beneficial role for aluminum in any extant organ-
ism, never mind human beings, and so to extrapolate presence to
essentiality without any mechanism may be more hopeful than
realistic. Hopeful because the consequences of an ever increasing
body burden of the biosphere’s most abundant ecotoxin and a
known human neurotoxin can only be detrimental, at least in the

























































Exley Aluminium and neurodegenerative disease
shorter term. The argument will concern the degree of severity
and not if aluminum is toxic. Another factor that also allows for a
degree of complacency about human exposure to aluminum is the
fact that aluminum is rarely acutely toxic in human beings. There
have been instances of acute, fatal, intoxications by aluminum and
most notably those known collectively as dialysis encephalopathy
(7). However, in everyday life human beings are not exposed to
levels of biologically available aluminum, which are responsible
for immediate acute effects. I have described aluminum as a silent
visitor to the human body perhaps only being noticed when spe-
cific toxicity thresholds are achieved. Indeed, a role for aluminum
in such an instance may not be noticed either immediately or at all.
If aluminum is not suspected as an etiological agent in a particular
condition then it is quite unlikely that its role in the disease will be
investigated.
WHAT ARE THE SYMPTOMS OF CHRONIC ALUMINUM
INTOXICATION IN HUMAN BEINGS?
It is probably correct to assume that aluminum toxicity will not
have a single motif or signature, which is specific to its actions. This
means that in the absence of any suspicion of a role for aluminum,a
physician is unlikely to (immediately) diagnose aluminum toxicity
in affected individuals. A lack of symptoms, which are immediately
recognizable as aluminum toxicity relates to the biological reactiv-
ity of Al3+(aq) and its significant propensity to be bound by oxygen-
based functional groups associated with myriad biomolecules (8).
These reactions will include the substitution of aluminum for
essential metals, the de novo binding of aluminum by non-specific
binding sites on protein-based biomolecules, and cross-linking
reactions involving biopolymers. Aluminum will also be bound
by labile molecules in both intracellular and extracellular milieus
and some of these interactions will involve its transportation as
high- and low-molecular weight complexes throughout the body
and, ultimately, the excretion of aluminum from the body (9).
The potential for aluminum to interact with and to influence so
many biochemical pathways means that the symptoms of its tox-
icity could be deficiency or sufficiency, agonistic or protagonistic,
and any combination of these and other physiology-based events.
The scientific literature does document links between aluminum
exposure and human disease and I recently compiled a table of
such conditions and these might be starting points in diagnosing
possible aluminum toxicity (10). However, for aluminum to play a
significant role in any disease-related event some degree of toxicity
threshold must have been achieved. Essentially, the rate of deliv-
ery of Al3+(aq) to target ligands must be sufficient to overcome the
inherent robustness of systems that are under attack. In achiev-
ing this threshold either aluminum must accumulate over time
within a particular compartment or possibly the administration of
a single dose of aluminum could achieve such a threshold instan-
taneously. The latter is probably more unusual in human being’s
everyday exposure to aluminum except, for example, where alu-
minum is administered as an adjuvant in vaccination and allergy
immunotherapy (11, 12).
HOW IS ALUMINUM GETTING INTO THE BRAIN?
The blood–brain-barrier sets the brain apart from the other organs
of the body. It is a selective barrier and its control over transport
of substances into and out of the brain has resulted in the brain
being populated by highly specialized post-mitotic cells or neu-
rones. Whether the chicken or the egg came first the outcome is
a unique organ of central importance to the functioning of most
of the rest of the human body. The observation that aluminum
enters the brain and accumulates with age reminds us that the
brain must have evolved in the absence of biologically available
aluminum and that only now with the advent of the aluminum
age is the brain having to cope with a burgeoning burden of brain
aluminum (13). Very little is understood as to how aluminum
enters the brain and as to which of the possible mechanisms of
entry are most significant (14). There will be movement of alu-
minum from the blood into the brain and so any activity, which
results in aluminum entering the bloodstream, will add to its brain
burden. The leakiness of the blood–brain-barrier to aluminum
will be influenced by its physiology, for example, the degree of
selectivity is expected to be lower in the fetus and neonate while
it may also be adversely affected in certain disease states includ-
ing aluminum-related disorders such as Alzheimer’s disease and
multiple sclerosis. Indeed, aluminum is known to increase the
leakiness of epithelial and endothelial barriers and in doing so
could concomitantly increase the passage of aluminum from the
blood to the brain (15). Blood to brain passage of aluminum is
a constant pressure on the brain aluminum burden and its over-
all significance may depend upon an individual’s body burden
of aluminum as well as their general health. Another route of
entry of aluminum to the brain is the olfactory system and the
movement of originally air-borne aluminum directly into the hip-
pocampus (16). This method of uptake of aluminum into the brain
becomes increasingly significant in individuals exposed to aerosols
of particulate aluminum, for example, occupational exposure to
aluminum dust (17). While the exposure is likely to be more spo-
radic than continuous exposure via the blood, it is also likely to
be more acute with the strong possibility of significant uptake of
aluminum over relatively shorter time periods, for example, years
as opposed to decades of exposure. Aluminum might also enter
the brain by diapedesis. For example, when aluminum adjuvants
are used in vaccination and allergy immunotherapy immune cells,
which infiltrate the injection site, are known to take up particulate
aluminum adjuvant by endocytosis and translocate such through-
out the body including into the brain via both paracellular and
transcellular processes (18). The result is the potential delivery of
significant quantities of adjuvant aluminum to the brain the fate
of which remains to be elucidated.
WHY IS THE BRAIN A LIKELY TARGET ORGAN FOR
ALUMINUM TOXICITY IN HUMAN BEINGS?
Neurones are the longest-lived cells of the human body and survive
aging processes, which ravage the remainder of the human body
(19). Evolution through natural selection has conferred biochem-
ical advantages upon neurones and the neuronal microenviron-
ment, which have in turn enabled human beings to live for longer.
I would contend that the evolution of what is an ostensibly immor-
tal cell line would not have occurred in the presence of biologically
available aluminum. Indeed, the advent of the aluminum age must
now have serious consequences for the health and longevity of
such a cell line. The lifespan of neurones predisposes them to a

























































Exley Aluminium and neurodegenerative disease
lifetime accumulation of aluminum. Evidence for intraneuronal
aluminum is incontrovertible though there is no consensus as to
the mechanism of its uptake from the neuronal microenvironment
(13). While a range of possible mechanisms are postulated none of
these have been demonstrated for neurones and only endocytosis is
confirmed for other cell types (20). The fate of intraneuronal alu-
minum is similarly obscure with evidence existing for its accumu-
lation in nuclear compartments, including nucleoli, its deposition
in lysosomes and other vesicle-based stores and its likely presence
in a number of chemical compartments such as cytosolic pools of
ATP and citrate (13). While neurones will accumulate aluminum it
is also possible that some intraneuronal aluminum may be secreted
from neuronal bodies as complexes with ligands such as ATP (21)
and neurotransmitters, specifically glutamate (22). It is probable
that the accumulation of aluminum in neurones accounts for a
burgeoning brain burden of aluminum over lifetimes. Extraneu-
ronal aluminum will move back into the periphery from the central
nervous system either by piggy-backing on transport systems mov-
ing substances out of the brain or simply by residual leakiness and
lymphatic drainage across the blood–brain-barrier. Thus, intra-
neuronal aluminum is both a sink for aluminum and a source of
biologically reactive aluminum. The latter may be effective both
at intraneuronal targets and, importantly, extraneuronal targets.
What this means is that the potency of aluminum as a neurotoxin
(concomitant with chronic lifetime exposure to aluminum) will be
dictated by an intraneuronal threshold acting inside and/or out-
side the neuronal body to bring about wholly degenerative effects
(23). The human brain is exposed to aluminum from the fetus
to the grave. While the proportion of this aluminum, which is
biologically available remains at a level, which can be endured
without precipitating significant biological effects aluminum tox-
icity will not be manifested. However, at some point, which will
be significantly influenced by individual circumstances, toxicity
will be exerted, brain systems will become dysfunctional and cas-
cades of events eventually leading to accelerated cell and neurone
loss will begin to dominate. This is when aluminum becomes a
neurotoxin (24).
WHAT ARE THE MECHANISMS OF NEUROTOXICITY?
To appreciate the neurotoxic potential of aluminum is to recog-
nize the myriad ways that biologically available aluminum can and
will interfere with normal brain metabolism. Aluminum, primar-
ily acting through Al3+(aq), is a generalist and will affect multiple
systems to bring about global changes influencing neuronal func-
tion and, ultimately survival. For example, biologically available
aluminum through the potentiation of damaging redox activity
(25) or the disruption of intracellular calcium signaling (26) will
systematically wear down cellular defenses. The mechanism of tox-
icity of aluminum is invariably biphasic with lower concentrations
producing toxic effects through stimulatory actions and higher
concentrations, resulting in inhibition of essential processes and
pathways (27). The omnipresence of a rogue metal ion, which is
able to compete with and replace other metals in essential processes
means that any chink in the armor of essential cellular systems
will be exacerbated by the additional presence of aluminum. Alu-
minum kicks a process while it is down and potentially prevents
it from getting back up again. The presence of aluminum in the
brain must mean that it is inevitable that it will contribute toward
any on-going degenerative conditions such as Alzheimer’s disease
or multiple sclerosis, ultimately, resulting in earlier onset and/or
more aggressive forms of the disease (17, 28). It is impossible with
the data, which are currently available to be precise about mech-
anisms underlying aluminum’s role in neurodegenerative disease.
It is probable that aluminum will affect early stages of diseases,
for example, influencing gene expression (29), with concomitant
effects upon functioning of neurones. However, it is unlikely that
chronic exposure to aluminum will induce necrotic cell death and
more likely to exert toxicity through stimulation and inducement
of mechanisms of cell death on the continuum that includes such
processes as autophagy and eventually apoptosis (30, 31). Alu-
minum helps to convince organelles and cells (neurones) that
they are better off committing suicide than continuing to fight
against their disruption and dysfunction. While the programed
destruction of organelles and cells will involve their deconstruc-
tion to leave discrete packages for further metabolism the fate
of aluminum in these processes is largely unknown though it is
unlikely that it will leave the brain and some of it may be found
in such structures as senile plaques, neurofibrillary tangles, Lewy
bodies, and lipofuscin. All of which are examples or signatures
(tombstones) of neurodegenerative disease (23).
SOLUTIONS
The advent of the aluminum age and the consequence of the
omnipresence of aluminum, not only in the environment but also
throughout the human body, is that we are all subject to chronic
aluminum intoxication. Every minute of each day we expend
energy coping with the presence of biologically reactive aluminum
in our bodies. The higher the body burden of aluminum the more
likely that this coping mechanism will manifest itself as disease.
In the brain, aluminum will contribute toward neurodegenerative
diseases including Alzheimer’s disease, Parkinson’s disease, and
multiple sclerosis. There is now a clear requirement for therapy
or treatment, which could lower the body burden of aluminum,
and particularly the aluminum content of the brain (32). It might,
therefore, be surprising to find that there are no drugs or chela-
tors, which have been developed and clinically approved for the
specific purpose of removing aluminum from the body. The iron
siderophore desferrioxamine (DFO) has been used in addressing
aluminum overload, and successfully so in one trial of Alzheimer’s
disease (33), and the general purpose metal chelator EDTA has
some efficacy in facilitating the urinary excretion of aluminum
(34). However, neither of these treatments is specific for aluminum
and neither has been used with the stated aim of lowering the body
burden of aluminum in healthy individuals. Surprising or other-
wise there is a real and urgent need for treatments, which will
facilitate the removal of aluminum from the body and preferably
without disrupting essential metals, such as iron. The treatment
should be as non-invasive as possible as it needs to be amenable to
healthy individuals and individuals with aluminum-related con-
ditions. It is equally important that the success of the treatment
can be measured quantitatively, which means that we also need
to fully understand the routes of excretion of aluminum from the
body and the treatment’s impact upon these routes. We need reli-
able and reproducible measures of the body burden of aluminum

























































Exley Aluminium and neurodegenerative disease
in order that the impact of it being reduced can be related to any
subsequent changes in health-related indices (6).
In the late 1980s, my Ph.D. research demonstrated the ame-
lioration of acute aluminum toxicity in fish by silicon (35). The
unique inorganic chemistry of the reaction of aluminum with
silicic acid [Si(OH)4] the only biologically available form of sil-
icon, has remained my life’s work and is now the subject of a
possible therapy to facilitate the removal of aluminum from the
human body (36). This therapy is based upon the observation that
drinking silicon-rich mineral waters increases the excretion of alu-
minum in urine (37). Silicon in mineral water (and indeed most
potable waters) is found mainly as silicic acid, which in the gut is
immediately absorbed and enters the blood before being excreted
in the urine via the kidney. Mirroring the urinary excretion of
silicic acid is aluminum and this close relationship suggests that
silicic acid in some way facilitates the excretion of aluminum via
the kidney. The mechanism of action remains to be elucidated
but it is thought to involve a pulse in silicic acid concentration in
the blood, which facilitates the passage of low-molecular weight
(<18 kDa) forms of aluminum across the glomeruli of the kidney.
The facilitation might involve the formation of hydroxyalumi-
nosilicates (HAS) as our most recent research on the speciation of
aluminum in blood identified a non-equilibrium phase of alu-
minum hydroxide (38), which is a necessary precursor to the
formation of HAS. While we have demonstrated this effect of
silicon-rich mineral waters in healthy and in diseased individuals
of all ages there remain a number of unresolved issues in relation to
the efficacy of this treatment as a long-term therapy to reduce the
body burden of aluminum. We need to establish if there is a lower
limit for the silicon content below which there is no concomitant
removal of aluminum from the body. At present, we have set this
limit at 30 mg/L “silica” (as usually written on bottles) or 14 mg/L
(0.5 mM) as silicon (silicic acid). We also need to understand the
volume of water, which should be drunk each day and whether or
not this volume should be taken as many small aliquots or several
large aliquots. Our default position at the moment is that a min-
imum of 1 L should be drunk each day and it should be taken as
only a few aliquots. While the majority of individuals who begin
to drink the mineral water, as recommended above, show imme-
diate increases in their urinary excretion of aluminum we do not
have excretion data beyond 7 weeks for healthy volunteers and we
do not know how long it will take for excretion data to indicate
statistically significant reductions in individual’s body burdens of
aluminum. While it is important that we obtain such data our
default position on this is that to achieve maximum protection
against everyday human exposure to aluminum the consumption
of a silicon-rich mineral water should become a normal part of
an individual’s diet and lifestyle. In a small cohort of individuals
with Alzheimer’s disease, we were able to demonstrate a statis-
tically significant reduction in their body burdens of aluminum
over 12 weeks of treatment while in their age and gender-matched
control population the reductions in body burden of aluminum
did not reach statistical significance in the same period (39). We
do not, of course, know if aluminum is being removed from all
of the body, for example, if it is being purged from the brain. The
assumption, which is as good as we can make at the moment, is
that all body stores of aluminum will be in some sort of dynamic
equilibrium with the blood and so the removal of aluminum from
the blood via the kidney will drive the removal of aluminum from
other tissues including the brain. Tentative support for the removal
of aluminum from the brain comes from our recent study on
Alzheimer’s disease where 3 out of 15 individuals with the disease
showed clinically relevant improvements in cognitive performance
by the end of the study (39). Up until very recently, we assumed
that the major route of elimination of systemic aluminum was in
urine. However, our recent observation of high concentrations of
aluminum in perspiration (40) may require a modification of this
assumption and will also require better understanding of whether
silicon-rich mineral waters might also facilitate the removal of
aluminum from the body in perspiration.
FUTURE PERSPECTIVES
We are living in an aluminum age and it is highly probable that
our use of aluminum will increase in the future (6). The parallel
recent histories of acid rain and intensive agriculture are imme-
diate testimonies to the ecotoxicity of a burgeoning biotic burden
of aluminum and it is inevitable that our increasing exposure to
aluminum will (continue to) impact upon human health. There
has been and there continues to be systematic attempts by the alu-
minum industry to suppress research on aluminum and human
health. While independent research in this field is prevented the
questions concerning human toxicity remain unanswered. Lack
of required research does not equate to lack of biological effect or
safety and neither does it implicate aluminum as a cause of human
disease. However, while our everyday exposure to aluminum may
not be the cause of any number of chronic human conditions it
most certainly can be and probably is a contributor to such dis-
eases. The evolution of modern human beings began in the absence
of biologically available aluminum and is now progressing in the
presence of a burgeoning body burden of what we know to be the
most ubiquitous and abundant ecotoxin on Earth. The aluminum
age is here to stay and it is now the responsibility of those organi-
zations charged with protecting the health of nations to introduce
legislation to limit human exposure to aluminum and so to ensure
that we can live safely and effectively alongside the World’s favorite
metal.
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